Company · Private
Biosplice Therapeutics
Targets splicing regulation to influence progenitor cell behaviour, with lead work in osteoarthritis.
EvidenceModerate
Listing
Private
Ticker
—
Headquarters
San Diego, US
Founded
2008
Technology
Alternative splicing / stem cell modulation
Category
Market cap
Private
Longevity thesis
Modulating resident stem cell behaviour may repair tissue without cell transplantation.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| Lorecivivint | NDA submitted | Knee osteoarthritis |
Recent developments
- 18 Jun 2026Reported structural endpoint data in knee osteoarthritis.
Scientific evidence
EvidenceModerate
Large human trials, mixed historical endpoint performance.
LONGEFI analysis
One of the few late-stage regenerative programmes with hard structural endpoints — a useful reality check for the whole field.
Analysis is research commentary. It is not investment advice or a recommendation.